Novo to Build $6 Billion Plant as Obesity Drug Demand Surges

Astra Enters Obesity Drug Race With Chinese Biotech Deal

New Ozempic Rival Is About to Make Your Weight Loss Drugs Cheaper

Eli Lilly Wins FDA Nod for Obesity Drug That Rivals Wegovy, Ozempic

European Stocks On Track for Best Run Since July on Fed Optimism

Novo Nordisk’s Earnings Surge on Frenzy for Obesity Drugs

When Japan Ends Negative Rate Policy, Treasuries Will Suffer

China Weight-Loss Drug Stocks Lose Shine on ‘Misleading’ Claims

A $245 Billion Selloff Signals Less Sparkly Future for Luxury Stocks

Novo’s Blockbuster Ozempic Now Shows Kidney Promise, Hitting Rivals 

LVMH Sales Growth Slows as Global Luxury Demand Cools

Ozempic Is Causing ‘Slight Pullback’ by Shoppers, Walmart Says